Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)

Annals of Hematology

Volumn 94, Issue 9, 2015, Pages 1441-1450

  Sandherr, Michael ^a   Hentrich, Marcus ^b   von Lilienfeld Toal, Marie ^c   Massenkeil, Gero ^d   Neumann, Silke ^e   Penack, Olaf ^f   Biehl, Lena ^g,h   Cornely, Oliver A ^g,i  

^a Gemeinschaftspraxis für Hämatologie und Onkologie   (Germany)

^b Spine Center   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d Klinik für Anästhesiologie Intensiv Notfall und Schmerzmedizin   (Germany)

^e Interdisziplinäres Ambulantes Onkologiezentrum   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Klinik I für Innere Medizin   (Germany)

^h Deutsches Zentrum für Infektionsforschung DZIF   (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antiviral prophylaxis; Cancer treatment; Guideline; Hepatitis B

Indexed keywords

ACICLOVIR; ADEFOVIR; ALEMTUZUMAB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BORTEZOMIB; ENTECAVIR; INFLUENZA VACCINE; LAMIVUDINE; MONOCLONAL ANTIBODY; NUCLEOTIDE; NUCLEOTIDE DERIVATIVE; PROTEASOME INHIBITOR; PURINE DERIVATIVE; STEROID;

ACUTE LEUKEMIA; ADENOVIRIDAE; ADENOVIRUS INFECTION; ANTIVIRAL PROPHYLAXIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; EVIDENCE BASED PRACTICE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; INFECTION RISK; INFLUENZA VACCINATION; LYMPHOPROLIFERATIVE DISEASE; MEDICAL SOCIETY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY VIRUS; SEASONAL INFLUENZA; SOLID TUMOR; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS REACTIVATION; ACUTE DISEASE; AUTOGRAFT; BREAST NEOPLASMS; FEMALE; GERMANY; HEMATOLOGY; LEUKEMIA; MALE; ONCOLOGY; STEM CELL TRANSPLANTATION; VIRUS DISEASES;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; AUTOGRAFTS; BREAST NEOPLASMS; FEMALE; GERMANY; HEMATOLOGY; HUMANS; LEUKEMIA; MALE; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; STEM CELL TRANSPLANTATION; VIRUS DISEASES;

EID: 84938738643     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2447-3     Document Type: Article

References (90)

1. Angarone M (2011) Epidemiology and prevention of viral infections in patients with hematologic malignancies. Infect Disord Drug Targets 11:27–33
2. Kunisaki KM, Janoff EN (2009) Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 9:493–504
3. Hajjar LA, Mauad T, Galas FR et al (2010) Severe novel influenza A (H1N1) infection in cancer patients. Ann Onco 21:2333–2341
4. Sandherr M, Einsele H, Hebart H et al (2006) Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 17:1051–1059
5. Baden LR, Bensinger W, Angarone M et al (2012) Prevention and treatment of cancer-related infections. J Natl Compr Cancer Netw 10:1412–1445
6. Flowers CR, Seidenfeld J, Bow EJ et al (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol 31:794–810
7. Kish MA (2001) Guide to development of practice guidelines. Clin Infect Dis 32:851–854
8. Kim ST, Park KH, Oh SC et al (2012) Varicella zoster virus infection during chemotherapy in solid cancer patients. Oncology 82:126–130
9. Hicks KL, Chemaly RF, Kontoyiannis DP (2003) Common community respiratory viruses in patients with cancer: more than just “common colds”. Cancer 97:2576–2587
10. Anaissie EJ, Mahfouz TH, Aslan T et al (2004) The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. Blood 103:1611–1617
11. Vento S, Cainelli F, Temesgen Z (2008) Lung infections after cancer chemotherapy. Lancet Oncol 9:982–992
12. Francisci D, Labianca R, Roila F (2010) Prevention and treatment of pandemic influenza in cancer patients. Ann Oncol 21:2301–2303
13. Ison MG (2011) Epidemiology, prevention, and management of influenza in patients with hematologic malignancy. Infect Disord Drug Targets 11:34–39
14. Meerveld-Eggink A, de Weerdt O, van der Velden AM et al (2011) Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol 22:2031–2035
15. Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M (2013) Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev 10:CD008983
16. Saral R, Burns WH, Prentice HG (1984) Herpes virus infections: clinical manifestations and therapeutic strategies in immunocompromised patients. Clin Haematol 13:645–660
17. Anderson H, Scarffe JH, Sutton RN, Hickmott E, Brigden D, Burke C (1984) Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. Br J Cancer 50:45–49
18. Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, Ellegaard J (1997) Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. J Clin Oncol Off J Am Soc Clin Oncol 15:2269–2274
19. Yahav D, Gafter-Gvili A, Muchtar E et al (2009) Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer 45:3131–3148
20. Styczynski J, Reusser P, Einsele H et al (2009) Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 43:757–770
21. Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P (2013) European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis 15:219–232
22. Yeo W, Chan PK, Zhong S et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299–307
23. Yeo W, Zee B, Zhong S et al (2004) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90:1306–1311
24. Huang YW, Chung RT (2012) Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Ther Adv Gastroenterol 5:359–370
25. Chen CY, Huang SY, Cheng A et al (2015) High risk of hepatitis B reactivation among patients with acute myeloid leukemia. PLoS One 10:e0126037
26. Yeo W, Chan PK, Hui P et al (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70:553–561
27. Yun J, Kim KH, Kang ES et al (2011) Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer 104:559–563
28. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 83:1627–1631
29. Cheng AL, Hsiung CA, Su IJ et al (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37:1320–1328
30. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT (2015) American Gastroenterological Association I. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:215–219, quiz e16-7
31. Marinone C, Mestriner M (2011) HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. Dig Liver Dis 43(Suppl 1):S49–S56
32. O’Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ (2003) Infections in patients with hematological cancer: recent developments. Hematology 438–72
33. Samonis G, Kontoyiannis DP (2001) Infectious complications of purine analog therapy. Curr Opin Infect Dis 14:409–413
34. Anaissie EJ, Kontoyiannis DP, O’Brien S et al (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559–566
35. Keating GM (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70:1445–1476
36. Held G, Poschel V, Pfreundschuh M (2006) Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Rev Anticancer Ther 6:1175–1186
37. Leung C, Tsoi E, Burns G, Sievert W (2011) An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. Oncologist 16:579–584
38. Tsutsumi Y, Yamamoto Y, Tanaka J, Asaka M, Imamura M, Masauzi N (2009) Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy 1:1053–1061
39. Mendez-Navarro J, Corey KE, Zheng H et al (2011) Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 31:330–339
40. Evens AM, Jovanovic BD, Su YC et al (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170–1180
41. Carson KR, Focosi D, Major EO et al (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816–824
42. Villa D, Gubbay J, Sutherland DR et al (2013) Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant. Leuk Lymphoma 54:1387–1395
43. Issa NC, Baden LR (2012) Current issues in vaccines for adult patients with hematologic malignancies. J Natl Compr Cancer Netw 10:1447–1454, quiz 54
44. Buensalido JA, Chandrasekar PH (2014) Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab. Expert Rev Anti-Infect Ther 12:151–154
45. European Association For The Study Of The L (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167–185
46. Artz AS, Somerfield MR, Feld JJ et al (2010) American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol Off J Am Soc Clin Oncol 28:3199–3202
47. Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Group EGW (2011) Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi59–vi63
48. McNamara C, Davies J, Dyer M et al (2012) Guidelines on the investigation and management of follicular lymphoma. Br J Haematol 156:446–467
49. Zelenetz AD, Abramson JS, Advani RH et al (2011) Non-Hodgkin’s lymphomas. J Natl Compr Cancer Netw 9:484–560
50. Buch MH, Aletaha D, Emery P, Smolen JS (2011) Reporting of long-term extension studies: lack of consistency calls for consensus. Ann Rheum Dis 70:886–890
51. Weinbaum CM, Mast EE, Ward JW (2009) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 49:S35–S44
52. Buch MH, Smolen JS, Betteridge N et al (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909–920
53. Zurawska U, Hicks LK, Woo G et al (2012) Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol Off J Am Soc Clin Oncol 30:3167–3173
54. Kumar A, Younes A (2014) Role of CD30 targeting in malignant lymphoma. Curr Treat Options in Oncol. doi:10.1007/s11864-014-0275-7
55. Cornely OA, Ullmann AJ, Karthaus M (2004) Opportunistic infections after treatment with monoclonal antibodies. Wien Med Wochenschr 154:209–217
56. Engelhardt M, Terpos E, Kleber M et al (2014) European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99:232–242
57. Chanan-Khan A, Sonneveld P, Schuster MW et al (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26:4784–4790
58. Swaika A, Paulus A, Miller KC et al (2012) Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol 10:155–159
59. Aoki T, Nishiyama T, Imahashi N, Kitamura K (2011) Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study. Jpn J Clin Oncol 41:876–881
60. Pour L, Adam Z, Buresova L et al (2009) Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 9:151–153
61. Vickrey E, Allen S, Mehta J, Singhal S (2009) Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 115:229–232
62. Casper C, Englund J, Boeckh M (2010) How I treat influenza in patients with hematologic malignancies. Blood 115:1331–1342
63. Rogers JE, Cumpston A, Newton M, Craig M (2011) Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transpl Infect Dis 13:480–484
64. Barton T, Collis T, Stadtmauer E, Schuster M (2001) Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 32:391–395
65. Holmberg LA, Boeckh M, Hooper H et al (1999) Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 94:4029–4035
66. Weissinger F, Auner HW, Bertz H et al (2012) Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 91:1161–1174
67. Novero A, Ravella PM, Chen Y, Dous G, Liu D (2014) Ibrutinib for B cell malignancies. Exp Hematol Oncol 3:4
68. Robak T, Robak P (2013) BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int Rev Immunol 32:358–376
69. Teplinsky E, Cheung D, Weisberg I et al (2013) Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Res Treat 141:167–172
70. Cervantes F, Vannucchi AM, Kiladjian JJ et al (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122:4047–4053
71. Wang ML, Blum KA, Martin P, et al (2015) Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood
72. D’Aniello C, Maruzzo M, Basso U (2013) Prevention of hepatitis B virus reactivation with lamivudine in a patient with advanced renal cell carcinoma treated with everolimus. Am J Ther
73. Sandherr M (2011) Antiviral agents in patients with haematological malignancies and acute respiratory failure. In: Azoulay E (ed) Pulmonary involvment in patients with haematological malignancies. Springer Verlag, Berlin, pp 589–595
74. Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M (2003) Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 31:51–55
75. Warkentin DI, Epstein JB, Campbell LM et al (2002) Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients. Ann Pharmacother 36:1525–1531
76. RKI Sa. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiologisches Bulletin 2013; Nr. 34:313-44
77. Pedrazzoli P, Baldanti F, Donatelli I et al (2014) Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM). Ann Oncol 25:1243–1247
78. Nordoy T, Aaberge IS, Husebekk A et al (2002) Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 19:71–78
79. Pollyea DA, Brown JM, Horning SJ (2010) Utility of influenza vaccination for oncology patients. J Clin Oncol 28:2481–2490
80. Mazza JJ, Yale SH, Arrowood JR et al (2005) Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 3:214–220
81. Rousseau B, Loulergue P, Mir O et al (2012) Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol 23:450–457
82. Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136:699–712
83. Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R (2012) Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer 20:2999–3008
84. Seto WK, Chan TS, Hwang YY et al (2014) Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 32:3736–3743
85. Ling WH, Soe PP, Pang AS, Lee SC (2013) Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer 108:1931–1935
86. Yeo W, Chan TC, Leung NW et al (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605–611
87. Liang R (2009) How I, treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113:3147–3153
88. Huang YH, Hsiao LT, Hong YC et al (2013) Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol Off J Am Soc Clin Oncol 31:2765–2772
89. Chen TT, Chiu CF, Yang TY et al (2015) Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy. Leuk Res 39:151–156
90. Li HC, Lo SY (2015) Hepatitis C virus: virology, diagnosis and treatment. World J Hepatol 7:1377–1389